In the fall of 1985, a very scary thing happened shortly after I was diagnosed with type 1 diabetes. One morning I woke up and I couldn't remember things I would normally remember. I couldn't remember the name of my neighbor's dog. I had a fanatical love for Cookie. Of course I would remember Cookie! A diabetic child would never forget such a sweet name for such an adorable dog! One more thing -- I had a pounding headache.

My mom brought me to the hospital, where my endocrinologist met us. They ran test after test and nary could an expert explain my memory loss. They confirmed I was experiencing amnesia, which turned out to be temporary because I was back to normal the next day.

How many people have experienced this same phenomenon? I surmised that this was my body reacting to the Humulin insulin I had started only a month or so before. The insulin must have been competing with my body's own attempts to generate insulin thus thwarting my blood sugar down into a dangerous hypoglycemic state. A study published in 1991 shows that hypoglycemia results in a lesion in the left temporal lobe. I have one of those lesions now, but it wasn't discovered until 2000. Oh yeah - and my peduncle is perfectly asymmetric. What does that mean anyway?

Why weren't doctors informed of this potential reaction to insulin in 1985? A study 6 years later is a few years too late. And how many more newly diagnosed insulin-dependent diabetics experience the same thing? My parents were scared out of their mind and nobody (including specialists) had any idea what to do with me.

Great strides have been made in the field of cardiology in recent years. However, according to a new study just out, people with diabetes remain dangerously at risk for heart-related problems like angina and heart attack. The results of the study have been published In the latest issue of the Journal of the American Medical Association (August 2007).

It's quite disturbing to read the numbers on this. Example? For every hundred diabetics who experience severe heart attack, just over eight will die within thirty days. For non-diabetics, that number goes down to around five. I could go on, but you get the picture.

The solution? Says the author of the study, Dr. Elliott M. Antman: "We need aggressive strategies to manage the diabetic population. What we need to do is everything to halt the epidemic of diabetes and find through research what therapies are most helpful for diabetic patients. We've got to do better for those patients." Hear, hear.

But what should those "aggressive strategies" be? And how do you implement them? That's the sticking point. The Washington Post caught the American Diabetes Association's Larry Deeb in a moment of remarkable frankness, saying he really doesn't know what can be done to get cardiologists and endocrinologists working together on this. C'mon, Larry. That's not exactly encouraging news for all the people out there with diabetes!

It's often said that serving food on smaller plates makes a diner inclined to eat less. Well, a Canadian researcher decided to put that theory to the test. Sue Pedersen, who is an endocrinologist at the University of Calgary, conducted a study designed to evaluate the efficacy of a specially designed "portion-control plate." The plates, designed by Diet Plate Limited of England, are marked with lines indicating how much of the day's main meal should be divided amongst the various food groups.

For six months, sixty-five study participants ate their food from regular dishes, while sixty-five others ate their food from the portion-control plates. All of the participants were type 2 diabetics and clinically obese. End result? The plates worked quite well at getting subjects to curb their appetites. After six months, those using the plates lost an average of 1.8 percent of their body weight, whereas the control group lost an average of only 0.1 percent. Interestingly, those on insulin regimens did the best of all, with an average of 2.5 percent weight loss.

The fatal flaw? What happens when the white lab coat crew aren't charting your intake any more? Call me a naysayer, but I'm predicting some major snacking in the future of those study subjects. Because special plate or not, you have to have the will to cut portion intake, and it's hard to maintain that will long-term.

The results of Pedersen's study have been published in the Archives of Internal Medicine (June 2007). Check out the Diet Plate website too.

Perhaps you feel the same way - but it's hard to catalogue the funny moments of life with diabetes. However the barometer sometimes registers off the chart when you mentally note the dialogue on doctor's visits.

I'd like to cite my newest friend (in my head) George, of the B.A.D Blog. He did an awesome blog on his doctor dropping a consoling F-bomb one day, after trying to explain erratic blood sugars to George. For those of you who are not familiar with the F-bomb...it is a four letter expletive. George's response was classic. He couldn't decide if that made his doctor cool or scary - but it did make him a little more human. George, like many of us, put doctors on an automatic pedestal akin to godlike.

Doctors, much like children, say the funniest things sometimes. It doesn't even have to be medically related - but when you ask a doctor something that is not related to their profession - you'll get a creative answer. Doctor's don't like to be wrong - but they'll give it their all before they admit defeat. I'd also like to thank George for the unrelenting entertainment.

Novartis SA reports the U.S. FDA has demanded additional data, including a clinical study in patients with kidney impairment, before giving Galvus its approval. Why the holdup?

The FDA wants more data studying Galvus in patients with impaired kidneys. It had been thought that Galvus might have an advantage because it is not processed by the kidneys, while Januvia is. But another molecule created when the body metabolizes Galvus does build up in the kidney.

In the Feb. 1 issue of The New England Journal of Medicine, David M. Nathan, a Harvard Medical School endocrinologist, noted that it was surprising that the FDA decided to clear Januvia at all, given the "paucity of published data from long-term clinical trials on its safety and efficacy." Nathan is a consultant for Novartis and other drug makers but not Merck.

There are several potential concerns about DPP-4 drugs, clear evidence has not turned up in clinical trials so far. The medicines could affect the immune system, because a receptor on immune cells is very similar to DPP-4. Merck says that Januvia was designed to bind only to the DPP-4 enzyme, reducing the chances of these side effects. Patients with impaired kidneys have more of the drug in their bloodstream and would be more likely to experience side effects.

The FDA has approved sitagliptin phosphate tablets to improve blood glucose levels in patients with type 2 diabetes. The drug, named Januvia, is proudly presented to the diabetic community by Merck and Co.

JANUVIA, a once-daily pill, enhances your body's natural ability to balance blood sugar levels. Your body sends important messages to your pancreas to try to balance high blood sugar. In response, your pancreas makes more insulin and signals the liver to make less sugar. But a substance in your body called DPP-4 blocks some of these important messages. JANUVIA works by blocking DPP-4, so more of the important messages get through. It also helps your pancreas make more insulin and signal your liver to make less sugar. Another feature of this new drug is the ability to prevent your sugar from going too low. JANUVIA works only when your blood sugar levels are high, or out of balance. When your blood sugar levels are at a healthy balance, JANUVIA doesn't have an effect. Because JANUVIA stops working before your blood sugar gets too low, it is not likely to lower your blood sugar to a potentially dangerous level (hypoglycemia). One more bonus to JANUVIA is the fact that this drug did not show weight gain in most patients during clinical trials.

Could this be the answer for your diabetes dilemma? Next time you swing by your doctor's office, mention that new drug Merck released. I'm sure your doctor will be as thrilled to see your numbers controlled as you'll be to see your natural ability to control them restored. Best of luck to those who find their diabetic solution in JANUVIA!

Anybody who has been granted the dubious distinction of multiple blood glucose readings a day will appreciate the lively approach my endocrinologist has applied to diabetes management. As his cartoon-depicted alter ego, Dr. Grady brings you straightforward explanations of the medical issues in the form of comic strips. His approach is the CartoonMD®, which is medical information made very, very simple.

A new class of diabetes agents was created and released on the market for patient care called the incretin mimetics. Greek to you, too? Exactly. Here's what I did -- take yourself a minute or two to pay homage to the comedic genius and frustrated artist that I proudly (and often) call doctor. If nothing more, you'll enjoy the momentary reminiscing of Saturday morning cartoons with an intellectual spin.

I encourage everybody to take a look at the educational entertainment from the good doctor, Dr. Grady. It truly is medical information that goes down easy!

Talk about a niche market! According to a press release just issued by the company, Pocket Reference Journals has released a braille reference guide for diabetics. The book's title is My Pocket Doctor: a Diabetic Reference Guide and Journal. The book (pictured) was written by an endocrinologist and registered dietitian who is also a certified diabetes educator. Pocket Reference Journals specializes in (surprise!) pocket sized health books, but this is the first one it has published in braille. The purpose of this particular book, My Pocket Doctor, is to provide helpful information about diabetes to those newly diagnosed who also are visually impaired. Okay, but why is the author not named if he/she is so well-qualified? That's my question.

My understanding is that this book can be ordered by contacting Pocket Reference Journals directly, either via the web or by phone at (714) 965-4570.